What’s the current market cap for BioNTech SE stock?

BioNTech SE (BNTX) has a market cap of $23bn as of June 28, 2026.

What is the P/E ratio for BioNTech SE stock?

The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 0 as of June 28, 2026.

Does BioNTech SE stock pay dividends?

No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of June 28, 2026.

When is the next BioNTech SE dividend payment date?

BioNTech SE (BNTX) stock does not pay dividends to its shareholders.

What is the beta indicator for BioNTech SE?

BioNTech SE (BNTX) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy BioNTech SE stock | $BNTX Share Price

About BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Ticker

$BNTX

Sector

Health

Primary listing

NASDAQ

Employees

7,807

Headquarters

Mainz, Germany

Website

www.biontech.de

BioNTech SE Metrics

BasicAdvanced

$23bn

-

-$5.82

1.37

-

What the Analysts think about BioNTech SE

Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.

Bulls say / Bears say

As of March 31, 2026, BioNTech held €16.8 billion in cash, cash equivalents and security investments and authorized a $1 billion ADS share buyback, underpinning its financial runway for continued R&D and pipeline advancement (StockTitan).

The company expects six late-stage pipeline data readouts in 2026 across immunomodulators, ADCs and mRNA cancer immunotherapies, providing multiple near-term catalysts for value creation (MarketScreener).

Interim Phase 2 data from the global ROSETTA Lung-02 trial showed pumitamig plus chemotherapy achieved confirmed objective response rates of 57.1% in non-squamous NSCLC and 68.4% in squamous NSCLC with 100% disease control, supporting its advancement into pivotal Phase 3 studies (SEC).

Q1 2026 revenues fell 35% year-on-year to €118.1 million, driven by lower COVID-19 vaccine sales, underscoring the revenue gap in the post-pandemic transition (down from €182.8 million in Q1 2025) (SecBot).

Net loss widened to an adjusted €494.6 million (IFRS net loss €531.9 million) in Q1 2026, reflecting higher R&D expenses of €651.6 million—up from €614.9 million a year earlier—underscoring heavy near-term cash burn on its oncology and ADC programs (PharmExec).

BioNTech plans to shutter multiple German production sites and cut up to 1,860 jobs as it exits COVID-19 vaccine manufacturing, risking operational disruption and incurring restructuring costs amid its strategic pivot (Reuters via onvista).

Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2026.

BioNTech SE Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

BioNTech SE Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

BioNTech SE News

AllArticlesVideos

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Reuters·2 weeks ago

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

MarketBeat·1 month ago

Germany says vaccine supply secure despite BioNTech production loss

Reuters·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About BioNTech SE

Ticker

Employees

BioNTech SE Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about BioNTech SE

Analyst Ratings

Bulls say / Bears say

BioNTech SE Financial Performance

Income Statement

BioNTech SE Earnings Performance

Earnings per share (EPS)

BioNTech SE News

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

Germany says vaccine supply secure despite BioNTech production loss

Buy $BNTX

Lightyear

Legal

Work with us

Bulls say / Bears say

BioNTech SE/$BNTX

About BioNTech SE

Ticker

Employees

BioNTech SE Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about BioNTech SE

Analyst Ratings

Bulls say / Bears say

BioNTech SE Financial Performance

Income Statement

BioNTech SE Earnings Performance

Earnings per share (EPS)

BioNTech SE News

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

Germany says vaccine supply secure despite BioNTech production loss

What’s the current market cap for BioNTech SE stock?

What is the P/E ratio for BioNTech SE stock?

Does BioNTech SE stock pay dividends?

When is the next BioNTech SE dividend payment date?

What is the beta indicator for BioNTech SE?

Bulls say / Bears say